Celcuity Corp - רווח נקי למניה (EPS TTM) CELC

Celcuity Inc. minimizes risks by combining the creation of cell-based assays with the development of targeted therapies. The YoY TTM growth in net income per share clearly demonstrates the dynamics of this process, with this metric reaching -28.00. However, pressure from pharma behemoths creates a threat of displacement. To balance its narrow specialization in diagnostic platforms, the company is expanding its own portfolio of anticancer agents.

This indicator measures earnings per share dynamics over a rolling twelve-month period, enabling the identification of hidden market imbalances through a daily recalculation of growth rates. Analyzing YoY TTM net income per share growth separates fundamental stability from short-term spikes, which is critical for Celcuity Inc. (CELC), as the market has already priced in its current operating expenses for cancer therapy development.